Greetings!

**The Quarterly Data Matters Training Newsletter is Back!**
The Data Matters Training Newsletter will be sent out quarterly in January, April, July and October.

**Multiple Myeloma and Lymphoma Questions**
As a reminder, any center emailing their CRC about a multiple myeloma question must fill out the disease tracker in Appendix G of the Data Manual. By filling out the tracker in advance, it allows the CRC to see the "big picture" and respond in a timely manner.

**Specific Instructions for the Reporting of Flow Cytometry for Multiple Myeloma and Lymphoma have been REMOVED from the Forms Instruction Manual**
Centers can now report negative Flow Cytometry Assessments for Multiple Myeloma and Lymphoma. Flow cytometry has improved over the years leading to increased sensitivity for reporting negative disease status.

- "yes" if flow cytometry was performed in the reporting period
- "no" if flow cytometry was not performed in the reporting period
- "not applicable" if flow was never performed since diagnosis or has never shown evidence of disease

Questions, feedback, or requests may be submitted directly on the manual website using the Feedback Feature at the bottom of each page. For more information on how to submit feedback, click here.

**The following forms are being revised / developed:**

<table>
<thead>
<tr>
<th>Form</th>
<th>Anticipated Release Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellular Therapy Product (4003)</td>
<td>Winter Release 2019</td>
</tr>
<tr>
<td>Recipient Death Data (2900)</td>
<td>Winter Release 2019</td>
</tr>
<tr>
<td>Indication for CRID Assignment (2814)</td>
<td>Spring Release 2019</td>
</tr>
<tr>
<td>BMT CTN 1702 Supplemental Form (2532) *</td>
<td>Spring Release 2019</td>
</tr>
<tr>
<td>SRG Study Contact Form *</td>
<td>Spring Release 2019</td>
</tr>
<tr>
<td>Tocilizumab Supplemental Form *</td>
<td>Spring Release 2019</td>
</tr>
<tr>
<td>CRID Assignment Form (2804)</td>
<td>Summer Release 2019</td>
</tr>
<tr>
<td>Pre-Transplant Essential Data (2400)</td>
<td>Summer Release 2019</td>
</tr>
<tr>
<td>Pre-TED Disease Classification (2402)</td>
<td>Summer Release 2019</td>
</tr>
<tr>
<td>Confirmation of HLA Typing (2005)</td>
<td>Summer Release 2019</td>
</tr>
<tr>
<td>HCT Infusion (2006)</td>
<td>Summer Release 2019</td>
</tr>
</tbody>
</table>
Post-Transplant Essential Data (2450) | Summer Release 2019
Plasma Cell Disorders/Multiple Myeloma (2016/2116) ** | Fall Release 2019

*New Form
**Accepting volunteers to help with Form Revision NOW

To volunteer for Form Revision review teams, get more information about the upcoming release, or comment on current form revisions, please contact: cibmtrformfeedback@nmdp.org

---

**Manual Helpful Hints: Red and Blue Callout Boxes**

The Forms Instruction Manual contains red and blue callout boxes that contain important reporting instructions or instructions on how to report specific scenarios. When reviewing the manual, please also review these boxes to prevent any reporting errors. See an example of these callout boxes below from the preparative regimen section on the pre-TED form (2400).

---

**Preparative Regimen – Drugs**
The following questions report the prescribed drug therapy that was part of the preparative regimen. Do not report the dose that was actually given. If the recipient has comprehensive report forms due, the actual dose given will be reported on the Recipient Baseline Form (Form 2000). Do not include drugs that are intended to offset the side effects of the chemotherapy (e.g., corticosteroids for nausea, MESNA for hemorrhagic cystitis, etc.).

**Drugs After Transplant**
Occasionally, protocols list drugs that may be given before and after transplant. If the drugs are planned to be given before and after transplant, only the doses given before transplant should be quantified in the preparative regimen section. The doses given after transplant should be reported in the Post-HCT Disease Therapy Planned as of Day 0 or GVHD Prophylaxis section. For example, if bortezomib or rituximab is planned to be given on Days -2, +1, +4, and +7, report the Day -2 dose in the preparative regimen section, and the post-transplant doses as planned post-HCT therapy.

---

**Quick Links**

CIBMTR Online Training webpage - to read course descriptions and access eLearning modules
CIBMTRRecipientForms@nmdp.org - to submit recipient forms and communications to CRCs
Look Up Your CRC - to discover who your assigned CRC is by entering your name and center
Past Newsletters and eBlasts - to refresh your memory on news we've sent
Cibmtrformfeedback@nmdp.org - send comments about forms or volunteering for forms revision

---

**CIBMTR on Facebook and Twitter**

Like us on Facebook and follow us on Twitter to stay up-to-date with important news and events. We promote our publications, share important content from other organizations, and advertise our key meetings and events. Join us today!

facebook.com/theCIBMTR
twitter.com/CIBMTR(@CIBMTR)

---

CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program®/Be The Match® and Medical College of Wisconsin.